PharmiWeb.com - Global Pharma News & Resources
22-Jan-2019

BRAFV600 Mutation Inhibiotors - Pipeline Insight, 2019 - ResearchAndMarkets.com

The "BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors

The report assesses the active BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors pipeline products by developmental stage, product type, molecule type, and administration route.

Topics Covered

1. Report Introduction

2. BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors Pipeline Products in Clinical Stages

6. BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment - Active Products

8. Inactive Pipeline Products

Companies Featured

  • Plexxikon
  • BeiGene
  • Deciphera Pharmaceuticals
  • Eli Lilly
  • Pfizer
  • Takeda
  • Novartis Pharmaceuticals Corporation
  • GlaxoSmithKline
  • Roche
  • Celldex Therapeutics Inc
  • Ambit Biosciences Corporation
  • Cephalon

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/9g4qvv/brafv600_mutation?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005422/en/

Editor Details

Last Updated: 22-Jan-2019